Clinical Trials Logo

Clinical Trial Summary

This study will refine and pilot the feasibility of introducing a thermal imaging test to detect fever in 100 patients being triaged within the Emergency Department. The only additional research requirement for the patient is to have a thermal image of their face taken. Other triage tests will be routine.

The aims of the feasibility study are to:

- Understand the acceptability of introducing the intervention within the Emergency Department setting

- Establish indicative patient recruitment numbers per week

- Determine the likely proportion of patients recruited from this group who have a high temperature

- Provide preliminary evidence that the technology can identify a high temperature in this diverse group of patients

- Provide preliminary data for machine learning training to support classification of patients as being with or without fever

The feasibility study will then inform the design and size of larger study to further develop and validate the the thermal imaging screening test to provide a 'with/ without' fever result.


Clinical Trial Description

Justification for research and project plan Background In the fifty years since the emergence of thermal imaging technology, Thales in Glasgow has built up a world leading capability in the design, manufacture and supply of Thermal Imaging cameras. In addition to the cameras, Thales in Glasgow has a particular expertise in developing image processing algorithms (conventional and artificial intelligence based) to allow the cameras to perform critical user tasks beyond mere imaging.

COVID-19 [SARS-COV-2] has placed a huge challenge on the world. In response to the crisis, Thales is engaged in a number of initiatives, including one aimed at the possible application of thermal imaging cameras to detect people with a fever and hence those who may be suffering from COVID-19. This initiative has received encouraging feedback from prospective users around the world who are looking, not only at the immediate issue in the hospitals, but also forward to a time beyond the current lockdowns, when cost effective techniques for surveying groups of people for potential COVID-19 sufferers will be required. This surveillance, for example, could be in hospitals, at airport gates, in buildings or outside in streets. As part of the initiative Thales Glasgow has been performing analysis and experiments using cameras looking at faces to confirm what temperature differences can be measured.

What Thales lacks is real world thermal images of patients suffering fever and access to clinicians who can advise on the medical aspects of the work. This research would fill these two voids.

Benefit and Rationale Existing thermal camera based fever detection systems suffer from two main issues that restrict their current application: Cost and Sensitivity.In order to achieve the required sensitivity, existing systems often require Black Body (BB) calibration sources to be visible in the scene. These BB sources are often more expensive than the cameras (circa one to two orders of magnitude more expensive). Thales believe they can achieve the required sensitivity without the need for BB sources by using advanced thermal camera correction algorithms.

The variability in skin emissivity makes conversions from irradiance as measured by a thermal camera, to absolute skin temperature inaccurate. Previous work place the emissivity of human skin between 0.990 and 0.999, however earlier research suggests that the value is 0.971 ± 0.005(SD). Typically in existing systems, this inaccurate, absolute temperature is used along with a simple threshold algorithm to find skin above a certain temperature leading to both false positives and false negatives.

Significant statistical correlation between the temperature of multiple facial features and measured human temperature has been observed. Their research found that for most facial features there was a correlation between multiple aspects of the facial view and recorded oral and tympanic temperature, with correlations of 0.5 or greater observed for multiple aspects of both the front and side of the face, with the ear offering the greatest statistical correlation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04397380
Study type Observational
Source NHS Greater Clyde and Glasgow
Contact David Lowe, MBChB
Phone 01414522930
Email david.lowe@nhs.net
Status Not yet recruiting
Phase
Start date May 20, 2020
Completion date July 1, 2020

See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2